Health and Neurodevelopmental Outcomes at 2 Years of Extremely Preterm Infants Enrolled in the International PLUSS Trial of Intratracheal Budesonide (PAS 2026) - Feb 25, 2026 - Abstract #2619.634; Pres time: Apr 25, 2026; 03:30 PM - 05:45 PM; Location: Poster Hall; "842/1059 (80%) children were alive at 2 years' CA, and the primary outcome is available for 967/1059 (91%). Assessed infants had a mean (SD) gestational age of 25.6 (1.4) weeks and birth weight 774 (197) g. Data are being analyzed in late 2025, and the primary outcome will be presented by group overall, and by gestational age subgroups ( < 26 weeks; 26-27 weeks).Conclusion(s): It is critical to assess longer-term outcomes for EP infants enrolled in randomized trials of corticosteroid medications. We will present the 2 year outcomes for the 1059 EP infants enrolled in the PLUSS trial of intratracheal budesonide mixed with surfactant."
Neurodevelopmental • Prematurity • Asthma • Bronchopulmonary Dysplasia • Cerebral Palsy • CNS Disorders • Developmental Disorders • Immunology • Ophthalmology • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases
|
|
Brett J. Manley; C. Omar F. Kamlin; Peter G. Davis; Kate L. Francis; Renae Allen; Katinka P. Bach; Risha Bhatia; Pita Birch; Jennifer A. Dawson; Koert de Waal; Callum Gately; Gayatri Jape; Brenda Law; Steven Resnick; Georg Schmolzer; Lex W. Doyle; Christopher JD. McKinlay; Jeanie Cheong
|